ERRATA

Alpha Interferon and Acyclovir Treatment of Herpes Simplex Virus in Lymphoid Cell Cultures

SCOTT M. HAMMER, JOAN C. KAPLAN, BRUCE R. LOWE, AND MARTIN S. HIRSCH

Infectious Disease Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114

Volume 21, no. 4, page 636: Figures 1 and 2 should be interchanged.

Pharmacokinetics of Cefonicid, a New Broad-Spectrum Cephalosporin

STEVEN L. BARRIERE, GERARD J. HATHEWAY, JOHN G. GAMBERTOGLIO, EMIL T. LIN, AND JOHN E. CONTE, JR.

Infectious Diseases Research Unit: Division of Clinical Pharmacy, Department of Pharmacy, School of Pharmacy, and the Clinical Infectious Diseases Unit, Department of Medicine, University of California, San Francisco, California 94143

Volume 21, no. 6, p. 937, column 2, line 50: “Conceivably, systemic infections may be adequately treated with doses of cefonicid given every 12 h” should read “Recent unpublished clinical trials using larger doses of cefonicid (1 to 2 g) than administered herein have demonstrated that single daily administration is efficacious in the management of most systemic infections.”

Inhibitors of DNA Precursor Metabolism in Dictyostelium discoideum

R. A. DEERING AND C. A. MICHRINA

Molecular and Cell Biology Program, The Pennsylvania State University, University Park, Pennsylvania 16802

Volume 21, no. 5, p. 765, column 1, Fig. 1 legend should read: FIG. 1. Growth of D. discoideum A3K in D-medium at 23°C in the presence of FUdR added at zero time. Concentrations of FUdR: ●, 0 μg/ml; △, 5 μg/ml; □, 10 μg/ml; ▽, 15 μg/ml; ○, 20 μg/ml. Thymidine was added in the following concentrations at zero time to the culture with 15 μg of FUdR per ml: ▼, 50 μg/ml; ■, 250 μg/ml. (15 μg of FUdR per ml is 6.1 × 10⁻⁵ M.)